Merck Serono S. A.

Santhera Pharmaceuticals (schweiz) Ag

Holger Deppe

Ulrich Abel

Andreas Goutopoulos

Meinolf Thiemann

Matthias Schwarz

Achim Feurer

Renate Sekul

Xuliang Jiang

Ulrich Graedler

Kerstin Otte

Ulrich Grädler

Cesare Mondadori

Inge Ott

Günther Metz

Sonja Nordhoff

Michael Soeberdt

Barbara Hoffmann-Enger

Philipp Weyermann

Hervé Siendt

Christian Rummey

Miroslav Terinek

Marco Henneböhle

Holger Herzner

The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

3-arylamino pyridine derivatives

The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.

Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists

The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds. 

Growing community of inventors

Heidelberg, Germany

Holger Deppe